Domainex releases new version of LeadBuilder virtual screening technology
Domainex, based in Cambridge, UK, has released the next generation of its LeadBuilder virtual screening technology.
Domainex, based in Cambridge, UK, has released the next generation of its LeadBuilder virtual screening technology.
LeadBuilder provides groups involved in translational research and biotech and pharma companies with rapid and cost-effective access to high-quality small-molecule drug leads, particularly against novel or difficult target proteins.
The latest enhancements include an expanded database of more than six million commercial compounds, and the incorporation of a number of software upgrades. Compounds which Domainex selects using LeadBuilder are purchased and tested in biochemical assays to give hit rates that are typically between 1-10% i.e. three orders of magnitude better than random, high-throughput screening (HTS).
"One of the most influential factors in determining whether or not a drug research project will be successful is the quality of the starting point, which is usually a screening hit," said Dr Trevor Perrior, research director of Domainex.
"By using LeadBuilder, we can make high-quality hits available to everyone without them needing to make an investment in the time and expense of high-throughput screening."